Breast NeoplasmsNCT07644910
Nudging Preventive Screening Via Message Framing and Bundling
A study testing Basic cancer screening message, Basic chronic disease test message and Basic combined message in people with Breast Neoplasms and Uterine Cervical Neoplasms, run by University of Chile.
Trial summary
This study is a randomized controlled field experiment embedded in the medical institution Early Diagnosis Program in Chile. Participants with two exams pending (a cancer screening test and a chronic disease test for diabetes and dyslipidemia) will be randomly assigned across a 3 × 3 factorial design: three message… Read more about this study
- Who is it for?
- Ages 21 to 74 years
- Conditions the study is for
- Breast Neoplasms, Uterine Cervical Neoplasms, Colorectal Neoplasms
- What is being tested?
- Basic cancer screening message, Basic chronic disease test message and Basic combined message
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 235,000 participants
- Where
- No sites listed yet
- Study dates
- 8 Jun 2026to 8 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 74 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Has at least one pending cancer screening (breast, colorectal, cervical, or prostate) within the contact window, as determined by the medical institution
- Aged 21 to 74 years
- Has a valid phone number on file
- Eligibility is determined operationally before randomization (ex-ante)
Who cannot join
- Participants whose WhatsApp message was not successfully delivered, as reported by the third-party software used by the medical institution.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
Daniel Schwartz Associate Professor, Department of Industrial Engineering, Ph.D. Behavioral Decision contact
About this study
Official title: The Effect of Message Framing and Screening Bundling on Preventive Screening Engagement: A Randomized Field Experiment
This study is a randomized controlled field experiment embedded in the medical institution Early Diagnosis Program in Chile. Participants with two exams pending (a cancer screening test and a chronic disease test for diabetes and dyslipidemia) will be randomly assigned across a 3 × 3 factorial design: three message framing conditions (Basic, Risk/Importance, Peace of Mind) crossed with three exam-type conditions (cancer screening only, chronic disease test only, or both exams). Participants with only a cancer screening pending will be assigned to the 3 framing conditions and be encouraged to get the cancer screening.
In both cases, participants are assigned to each experimental arm at twice the rate of an additional arm receiving the standard message currently used by the medical institution. This standard-message arm is included for operational purposes, is not part of the pre-specified analyses, and is thus not described in the "Arms and Intervention" section (or counted for "number of arms").
Read the detailed description
The investigators will conduct a randomized controlled trial in the domain of preventive care engagement. Participants with two exams pending (a cancer screening test and a chronic disease test for diabetes and dyslipidemia) will be randomly assigned to a 3 × 3 factorial design. The first factor manipulates message framing, randomly assigning participants to receive either (i) a standard Whatsapp message, (ii) a Whatsapp message emphasizing age-related health risks and the importance of early detection, or (iii) a message emphasizing the potential peace of mind associated with completing screening. The second factor manipulates the type of exam highlighted in the outreach, randomly assigning participants to receive outreach focused on (i) cancer screening only, (ii) chronic disease testing only, or (iii) both cancer screening and chronic disease testing. Patients who have only one pending cancer exam are randomly assigned across the three message framing conditions only and are encouraged to get the cancer screening.
The experiment will test two sets of research questions.
Question 1. How does emphasizing different motivations for completing cancer screening affect patient engagement?
H1a. This study will test how messages emphasizing age-based health risks and the importance of early detection affect cancer screening engagement, relative to a basic message. Emphasizing health risks may increase perceived urgency and boost engagement; however, prior work on information avoidance suggests this framing may instead prompt avoidance of screening-related information and reduce engagement.
H1b. This study will test whether messages emphasizing that completing screening can bring peace of mind increase engagement relative to a basic message.
H1c. This study will test whether the effects of the two framing manipulations on cancer screening differ when the same messaging strategies are applied to chronic disease testing.
Question 2. How does combining recommendations for multiple preventive tests affect patient engagement? H2a. This study will examine the impact of bundling multiple tests (vs. single test) on patient engagement.
H2b. This study will test whether pairing cancer screening with a chronic disease testing recommendation affects cancer screening engagement. Recommending multiple tests may increase the perceived value of engaging with the healthcare system, boosting engagement with cancer screening; alternatively, patients may find the message more overwhelming or burdensome, reducing engagement with cancer screening.
H2c. This study will test whether pairing chronic disease testing with a cancer screening recommendation affects chronic disease testing engagement. Pairing may increase perceived value and make chronic disease testing seem less emotionally aversive, thus increasing engagement with chronic disease testing; alternatively, combining multiple recommendations may feel burdensome and reduce engagement with chronic disease testing.
The investigators will run ordinary least squares regressions (OLS) with robust standard errors to predict each outcome variable.
To test questions 1a and 1b, the study will focus on participants assigned to the cancer-screening-only condition, and the primary predictors of interest are indicators for whether participants are assigned to the Risk/Importance message condition or the Peace-of-Mind condition (with the Basic message condition as the reference group).
To test question 1c, the investigators will pool participants assigned to the cancer-screening-only and chronic-disease-only conditions and estimate models that include framing-condition indicators, an exam-type indicator, and their interactions.
To test question 2a, the investigators will focus on participants assigned to either cancer-screening-only condition, the chronic-disease-only condition, or the both-exams condition. The key independent variable will be an indicator for assignment to the both-exam condition (vs. the other two conditions combined as reference group). If this indicator is statistically significant, the investigators will compare the both-exam condition separately with cancer-screening-only condition and the chronic-disease-only condition.
To test question 2b, the study will focus on participants assigned to either the cancer-screening-only condition or the both-exams condition. The key independent variable will be an indicator for assignment to the both-exam condition.
To test question 2c, the study will focus on participants who received a message about chronic disease testing, including both those assigned to the chronic-disease-only condition and those assigned to the both-exams condition. The key independent variable will be an indicator for assignment to the both-exams condition.
Questions 1c-2c will only include participants with two exams pending (a cancer screening test and a chronic disease test for diabetes and dyslipidemia).
All regressions will be run with and without control variables, including number of pending exam fixed effects, age (continuous), gender, insurance type (public or private based on the local health insurance plans), and clinic or region indicators if available. For robustness, the investigators will conduct logit models as well.
Additionally, the study will explore whether the peace-of-mind message is more effective than the risk/importance message by comparing the coefficients on indicators for the risk/importance message and the peace-of-mind message in regressions described in the analysis.
Also, the investigators will examine whether the effects of the messaging manipulations on cancer screening engagement change when patients are simultaneously encouraged to complete both a cancer screening and chronic disease testing, relative to when they are only encouraged to complete a cancer screening. The regressions will include indicators for message types (risk/importance and peace of mind, relative to basic), an indicator for whether patients are recommended to take multiple tests (vs. just a cancer screening), and their interaction terms to predict (1) whether the patient indicates interest (by either clicking "Yes, I want help" or providing an equivalent affirmative response in Whatsapp) within 7 days, (2) whether the patient schedules the recommended cancer screening within 7 days, and (3) whether the patient completes the recommended cancer screening within 12 weeks.
Given that the experimental design addresses multiple distinct research questions, the analyses may ultimately be split across two papers focused on different sets of questions, particularly if including all analyses in a single paper would limit clarity or coherence.
The experiment is expected to last for 60 working days and reach 235,000 patients across all arms (including the standard-message arm that is not part of the study of interest). About 145,000 of these patients have two pending exams (cancer screening+chronic disease testing), and 90,000 patients have a pending cancer screening.
As an exploratory analysis, the investigators will examine patients' prior frequency of cancer and chronic disease screening as a potential moderator of intervention effects.
- Conditions
- Breast Neoplasms, Uterine Cervical Neoplasms, Colorectal Neoplasms, Prostatic Neoplasms, Diabetes Mellitus, Dyslipidemias
- Being tested
- Basic cancer screening message, Basic chronic disease test message, Basic combined message, Risk framing cancer screening message, Risk framing chronic disease test message
- Keywords
- Behavioral science, randomized controlled trial, WhatsApp patient outreach, message framing, information avoidance, cancer screening, chronic disease testing, preventive care
- Medical subject headings
- Breast Neoplasms, Uterine Cervical Neoplasms, Colorectal Neoplasms, Prostatic Neoplasms, Diabetes Mellitus, Dyslipidemias
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Basic cancer screening messageBehavioural
Patients receive a WhatsApp message naming their recommended cancer screening exam and describing it as the test recommended for their age group.
Basic chronic disease test messageBehavioural
Patients receive a WhatsApp message naming the recommended chronic disease test and describing it as the test recommended for their age group.
Basic combined messageBehavioural
Patients receive a WhatsApp message naming both the recommended cancer screening and the chronic disease test, and describing them as the tests recommended for their age group.
Risk framing cancer screening messageBehavioural
Patients receive a WhatsApp message naming their recommended cancer screening exam and emphasizing that (1) the recommendation is based on health risks common to their age group and (2) early detection can be life-saving
Risk framing chronic disease test messageBehavioural
Patients receive a WhatsApp message naming the recommended chronic disease test and emphasizing that (1) the recommendation is based on health risks common to their age group and (2) early detection can be life-saving.
Risk framing combined messageBehavioural
Patients receive a WhatsApp message naming both exams and emphasizing that (1) the recommendation is based on health risks common to their age group and (2) early detection can be life-saving.
Peace of mind framing cancer screening messageBehavioural
Patients receive a WhatsApp message naming their recommended cancer screening exam and emphasizing that getting the exam done on time will give them peace of mind about their health.
Peace of mind framing chronic disease test messageBehavioural
Patients receive a WhatsApp message naming the recommended chronic disease and emphasizing that getting the exam done on time will give them peace of mind about their health.
Peace of mind framing combined messageBehavioural
Patients receive a WhatsApp message naming both exams and emphasizing that getting the exams done on time will give them peace of mind about their health.
| Study group | Role | What they receive |
|---|---|---|
| Basic/Control × Cancer | Active comparator | Basic cancer screening message Receives: Behavioral: Basic cancer screening message |
| Basic/Control × chronic disease test | Active comparator | Basic chronic disease test message Receives: Behavioral: Basic chronic disease test message |
| Basic/Control × Both | Active comparator | Basic combined message Receives: Behavioral: Basic combined message |
| Risk/Importance × Cancer | Experimental | Risk framing cancer screening message Receives: Behavioral: Risk framing cancer screening message |
| Risk/Importance × Chronic Disease Test | Experimental | Risk framing chronic disease test message Receives: Behavioral: Risk framing chronic disease test message |
| Risk/Importance × Both | Experimental | Risk framing combined message Receives: Behavioral: Risk framing combined message |
| Peace of Mind × Cancer screening | Experimental | Peace of mind framing cancer screening message Receives: Behavioral: Peace of mind framing cancer screening message |
| Peace of Mind × chronic disease Test | Experimental | Peace of mind framing chronic disease test message Receives: Behavioral: Peace of mind framing chronic disease test message |
| Peace of Mind × Both | Experimental | Peace of mind framing combined message Receives: Behavioral: Peace of mind framing combined message |
What is being measured
The primary outcome is the main question the study is designed to answer.
Screening Engagement Response
Binary indicator of whether the patient clicks "Yes, I want help" or provides an equivalent affirmative response via WhatsApp within 7 days of receiving the message (1), or does not take either action (0). Used to test H1a, H1b, H1c, and H2a.
Measured: 7 days after message delivery
Cancer Screening Appointment
Binary indicator of whether the patient schedules the recommended cancer screening exam within 7 days of receiving the message (1) or does not (0). Used to test H2b
Measured: 7 days after message delivery
Chronic Disease Testing Appointment
Binary indicator of whether the patient schedules the recommended chronic disease test within 7 days of receiving the message (1) or does not (0). Used to test H2c.
Measured: 7 days after message delivery
Secondary outcomes (6)
Screening Appointment Scheduling
Binary indicator of whether the patient schedules the specific test recommended in the message within 7 days of receiving it (1) or does not (0). Used to test H1a, H1b, and H1c.
Measured: 7 days after message delivery
Screening Test Completion
Binary indicator of whether the patient completes the specific test recommended in the message within 12 weeks of receiving it (1) or does not (0). Used to test H1a, H1b, and H1c
Measured: 12 weeks after message delivery
Any Test Appointment Scheduling
Binary indicator of whether the patient schedules any of the tests recommended in the message within 7 days of receiving it (1) or does not (0). Used to test H2a.
Measured: 7 days after message delivery
Any Test Completion
Binary indicator of whether the patient completes any of the tests recommended in the message within 12 weeks of receiving it (1) or does not (0). Used to test H2a.
Measured: 12 weeks after message delivery
Cancer Screening Completion
Binary indicator of whether the patient completes the recommended cancer screening exam within 12 weeks of receiving the message (1) or does not (0). Used to test H2b
Measured: 12 weeks after message delivery
Chronic Disease Test Completion
Binary indicator of whether the patient completes the recommended chronic disease test within 12 weeks of receiving the message (1) or does not (0). Used to test H2c.
Measured: 12 weeks after message delivery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Jun 2026
- Study start8 Jun 2026 (estimated)
- Primary completion8 Sep 2026 (estimated)
- Study completion8 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Breast NeoplasmsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Factorial
- Model description
- Patients with two exams pending (a cancer screening test and a chronic disease test for diabetes and dyslipidemia) will be randomly assigned across a 3 × 3 factorial design: three message framing conditions (Basic, Risk/Importance, Peace of Mind) crossed with three exam-type conditions (cancer screening only, chronic disease test only, or both exams). Participants with only a cancer screening pending will be assigned to the 3 framing conditions and be encouraged to get the cancer screening. In both cases, participants are assigned to each experimental arm at twice the rate of an additional arm receiving the standard message currently used by the medical institution. This standard-message arm is included for operational purposes and is not part of the pre-specified analyses.
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 235,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Chile
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Daniel Schwartz, University of Chile
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07644910
- Sponsor's protocol ID
- Message Framing for Screening
- Status last verified
- Jun 2026
- First submitted
- 8 Jun 2026
- Last updated
- 17 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be shared due to institutional restrictions that prohibit data disclosure, even in anonymized form
Study at a glance
From the registry record, last updated by the sponsor on 17 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of Message Framing and Screening Bundling on Preventive Screening Engagement: A Randomized Field Experiment
- ClinicalTrials.gov ID
- NCT07644910
- Acronym / sponsor ID
- Message Framing for Screening
- Conditions
- Breast Neoplasms, Uterine Cervical Neoplasms, Colorectal Neoplasms, Prostatic Neoplasms, Diabetes Mellitus, Dyslipidemias
- Keywords
- Behavioral science, randomized controlled trial, WhatsApp patient outreach, message framing, information avoidance, cancer screening, chronic disease testing, preventive care
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 235,000 participants (estimated)
- Lead sponsor
- University of ChileUniversity, hospital or other
- Study start
- 8 Jun 2026 (estimated)
- Primary completion
- 8 Sep 2026 (estimated)
- Study completion
- 8 Dec 2026 (estimated)
- First posted
- 12 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is a randomized controlled field experiment embedded in the medical institution Early Diagnosis Program in Chile. Participants with two exams pending (a cancer screening test and a chronic disease test for diabetes and dyslipidemia) will be randomly assigned across a 3 × 3 factorial design: three message framing conditions (Basic, Risk/Importance, Peace of Mind) crossed with three exam-type conditions (cancer screening only, chronic disease test only, or both exams). Participants with only a cancer screening pending will be assigned to the 3 framing conditions and be encouraged to get the cancer screening.
In both cases, participants are assigned to each experimental arm at twice the rate of an additional arm receiving the standard message currently used by the medical institution. This standard-message arm is included for operational purposes, is not part of the pre-specified analyses, and is thus not described in the "Arms and Intervention" section (or counted for "number of arms").
Detailed description
The investigators will conduct a randomized controlled trial in the domain of preventive care engagement. Participants with two exams pending (a cancer screening test and a chronic disease test for diabetes and dyslipidemia) will be randomly assigned to a 3 × 3 factorial design. The first factor manipulates message framing, randomly assigning participants to receive either (i) a standard Whatsapp message, (ii) a Whatsapp message emphasizing age-related health risks and the importance of early detection, or (iii) a message emphasizing the potential peace of mind associated with completing screening. The second factor manipulates the type of exam highlighted in the outreach, randomly assigning participants to receive outreach focused on (i) cancer screening only, (ii) chronic disease testing only, or (iii) both cancer screening and chronic disease testing. Patients who have only one pending cancer exam are randomly assigned across the three message framing conditions only and are encouraged to get the cancer screening.
The experiment will test two sets of research questions.
Question 1. How does emphasizing different motivations for completing cancer screening affect patient engagement?
H1a. This study will test how messages emphasizing age-based health risks and the importance of early detection affect cancer screening engagement, relative to a basic message. Emphasizing health risks may increase perceived urgency and boost engagement; however, prior work on information avoidance suggests this framing may instead prompt avoidance of screening-related information and reduce engagement.
H1b. This study will test whether messages emphasizing that completing screening can bring peace of mind increase engagement relative to a basic message.
H1c. This study will test whether the effects of the two framing manipulations on cancer screening differ when the same messaging strategies are applied to chronic disease testing.
Question 2. How does combining recommendations for multiple preventive tests affect patient engagement? H2a. This study will examine the impact of bundling multiple tests (vs. single test) on patient engagement.
H2b. This study will test whether pairing cancer screening with a chronic disease testing recommendation affects cancer screening engagement. Recommending multiple tests may increase the perceived value of engaging with the healthcare system, boosting engagement with cancer screening; alternatively, patients may find the message more overwhelming or burdensome, reducing engagement with cancer screening.
H2c. This study will test whether pairing chronic disease testing with a cancer screening recommendation affects chronic disease testing engagement. Pairing may increase perceived value and make chronic disease testing seem less emotionally aversive, thus increasing engagement with chronic disease testing; alternatively, combining multiple recommendations may feel burdensome and reduce engagement with chronic disease testing.
The investigators will run ordinary least squares regressions (OLS) with robust standard errors to predict each outcome variable.
To test questions 1a and 1b, the study will focus on participants assigned to the cancer-screening-only condition, and the primary predictors of interest are indicators for whether participants are assigned to the Risk/Importance message condition or the Peace-of-Mind condition (with the Basic message condition as the reference group).
To test question 1c, the investigators will pool participants assigned to the cancer-screening-only and chronic-disease-only conditions and estimate models that include framing-condition indicators, an exam-type indicator, and their interactions.
To test question 2a, the investigators will focus on participants assigned to either cancer-screening-only condition, the chronic-disease-only condition, or the both-exams condition. The key independent variable will be an indicator for assignment to the both-exam condition (vs. the other two conditions combined as reference group). If this indicator is statistically significant, the investigators will compare the both-exam condition separately with cancer-screening-only condition and the chronic-disease-only condition.
To test question 2b, the study will focus on participants assigned to either the cancer-screening-only condition or the both-exams condition. The key independent variable will be an indicator for assignment to the both-exam condition.
To test question 2c, the study will focus on participants who received a message about chronic disease testing, including both those assigned to the chronic-disease-only condition and those assigned to the both-exams condition. The key independent variable will be an indicator for assignment to the both-exams condition.
Questions 1c-2c will only include participants with two exams pending (a cancer screening test and a chronic disease test for diabetes and dyslipidemia).
All regressions will be run with and without control variables, including number of pending exam fixed effects, age (continuous), gender, insurance type (public or private based on the local health insurance plans), and clinic or region indicators if available. For robustness, the investigators will conduct logit models as well.
Additionally, the study will explore whether the peace-of-mind message is more effective than the risk/importance message by comparing the coefficients on indicators for the risk/importance message and the peace-of-mind message in regressions described in the analysis.
Also, the investigators will examine whether the effects of the messaging manipulations on cancer screening engagement change when patients are simultaneously encouraged to complete both a cancer screening and chronic disease testing, relative to when they are only encouraged to complete a cancer screening. The regressions will include indicators for message types (risk/importance and peace of mind, relative to basic), an indicator for whether patients are recommended to take multiple tests (vs. just a cancer screening), and their interaction terms to predict (1) whether the patient indicates interest (by either clicking "Yes, I want help" or providing an equivalent affirmative response in Whatsapp) within 7 days, (2) whether the patient schedules the recommended cancer screening within 7 days, and (3) whether the patient completes the recommended cancer screening within 12 weeks.
Given that the experimental design addresses multiple distinct research questions, the analyses may ultimately be split across two papers focused on different sets of questions, particularly if including all analyses in a single paper would limit clarity or coherence.
The experiment is expected to last for 60 working days and reach 235,000 patients across all arms (including the standard-message arm that is not part of the study of interest). About 145,000 of these patients have two pending exams (cancer screening+chronic disease testing), and 90,000 patients have a pending cancer screening.
As an exploratory analysis, the investigators will examine patients' prior frequency of cancer and chronic disease screening as a potential moderator of intervention effects.
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- Single blind (participant)
- Number of arms
- 9
- Model description
- Patients with two exams pending (a cancer screening test and a chronic disease test for diabetes and dyslipidemia) will be randomly assigned across a 3 × 3 factorial design: three message framing conditions (Basic, Risk/Importance, Peace of Mind) crossed with three exam-type conditions (cancer screening only, chronic disease test only, or both exams). Participants with only a cancer screening pending will be assigned to the 3 framing conditions and be encouraged to get the cancer screening. In both cases, participants are assigned to each experimental arm at twice the rate of an additional arm receiving the standard message currently used by the medical institution. This standard-message arm is included for operational purposes and is not part of the pre-specified analyses.
| Arm | Type | Receives |
|---|---|---|
| Basic/Control × Cancer | Active comparator | Behavioral: Basic cancer screening messageBasic cancer screening message |
| Basic/Control × chronic disease test | Active comparator | Behavioral: Basic chronic disease test messageBasic chronic disease test message |
| Basic/Control × Both | Active comparator | Behavioral: Basic combined messageBasic combined message |
| Risk/Importance × Cancer | Experimental | Behavioral: Risk framing cancer screening messageRisk framing cancer screening message |
| Risk/Importance × Chronic Disease Test | Experimental | Behavioral: Risk framing chronic disease test messageRisk framing chronic disease test message |
| Risk/Importance × Both | Experimental | Behavioral: Risk framing combined messageRisk framing combined message |
| Peace of Mind × Cancer screening | Experimental | Behavioral: Peace of mind framing cancer screening messagePeace of mind framing cancer screening message |
| Peace of Mind × chronic disease Test | Experimental | Behavioral: Peace of mind framing chronic disease test messagePeace of mind framing chronic disease test message |
| Peace of Mind × Both | Experimental | Behavioral: Peace of mind framing combined messagePeace of mind framing combined message |
Who may qualify
- Ages
- 21 to 74 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Has at least one pending cancer screening (breast, colorectal, cervical, or prostate) within the contact window, as determined by the medical institution
- Aged 21 to 74 years
- Has a valid phone number on file
- Eligibility is determined operationally before randomization (ex-ante)
Key exclusion criteria (1 listed)
- Participants whose WhatsApp message was not successfully delivered, as reported by the third-party software used by the medical institution.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Basic cancer screening messagePatients receive a WhatsApp message naming their recommended cancer screening exam and describing it as the test recommended for their age group. | Behavioural | Basic/Control × Cancer |
| Basic chronic disease test messagePatients receive a WhatsApp message naming the recommended chronic disease test and describing it as the test recommended for their age group. | Behavioural | Basic/Control × chronic disease test |
| Basic combined messagePatients receive a WhatsApp message naming both the recommended cancer screening and the chronic disease test, and describing them as the tests recommended for their age group. | Behavioural | Basic/Control × Both |
| Risk framing cancer screening messagePatients receive a WhatsApp message naming their recommended cancer screening exam and emphasizing that (1) the recommendation is based on health risks common to their age group and (2) early detection can be life-saving | Behavioural | Risk/Importance × Cancer |
| Risk framing chronic disease test messagePatients receive a WhatsApp message naming the recommended chronic disease test and emphasizing that (1) the recommendation is based on health risks common to their age group and (2) early detection can be life-saving. | Behavioural | Risk/Importance × Chronic Disease Test |
| Risk framing combined messagePatients receive a WhatsApp message naming both exams and emphasizing that (1) the recommendation is based on health risks common to their age group and (2) early detection can be life-saving. | Behavioural | Risk/Importance × Both |
| Peace of mind framing cancer screening messagePatients receive a WhatsApp message naming their recommended cancer screening exam and emphasizing that getting the exam done on time will give them peace of mind about their health. | Behavioural | Peace of Mind × Cancer screening |
| Peace of mind framing chronic disease test messagePatients receive a WhatsApp message naming the recommended chronic disease and emphasizing that getting the exam done on time will give them peace of mind about their health. | Behavioural | Peace of Mind × chronic disease Test |
| Peace of mind framing combined messagePatients receive a WhatsApp message naming both exams and emphasizing that getting the exams done on time will give them peace of mind about their health. | Behavioural | Peace of Mind × Both |
Primary outcome
Screening Engagement Response
Time frame: 7 days after message delivery
Binary indicator of whether the patient clicks "Yes, I want help" or provides an equivalent affirmative response via WhatsApp within 7 days of receiving the message (1), or does not take either action (0). Used to test H1a, H1b, H1c, and H2a.
Cancer Screening Appointment
Time frame: 7 days after message delivery
Binary indicator of whether the patient schedules the recommended cancer screening exam within 7 days of receiving the message (1) or does not (0). Used to test H2b
Chronic Disease Testing Appointment
Time frame: 7 days after message delivery
Binary indicator of whether the patient schedules the recommended chronic disease test within 7 days of receiving the message (1) or does not (0). Used to test H2c.
6 secondary outcomes
Screening Appointment Scheduling
Time frame: 7 days after message delivery
Screening Test Completion
Time frame: 12 weeks after message delivery
Any Test Appointment Scheduling
Time frame: 7 days after message delivery
Any Test Completion
Time frame: 12 weeks after message delivery
Cancer Screening Completion
Time frame: 12 weeks after message delivery
Chronic Disease Test Completion
Time frame: 12 weeks after message delivery
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Jun 2026.
- Individual participant dataSharing planned: No. Individual participant data will not be shared due to institutional restrictions that prohibit data disclosure, even in anonymized form
Related trials for Breast Neoplasms
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
RecruitingPhase 2
Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder
Adjustment Disorder, Adjustment Disorder With Anxious Mood
Recruiting
Evaluation of the Effect of Using Ultrasound Robots for Breast Cancer Screening
Breast Cancer, Ultrasound
RecruitingPhase 3
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Metastatic Breast Cancer
Active, not recruiting
Interest of Broadband Spectroscopy Analysis by Infrared Laser on Liquid Biopsies in Breast Cancer Screening
Breast Cancer Female, BRCA1 Mutation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Daniel Schwartz Associate Professor, Department of Industrial Engineering, Ph.D. Behavioral Decision contact
Questions about this trial
What is this clinical trial studying?
A study testing Basic cancer screening message, Basic chronic disease test message and Basic combined message in people with Breast Neoplasms and Uterine Cervical Neoplasms, run by University of Chile.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 17 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Daniel Schwartz Associate Professor, Department of Industrial Engineering, Ph.D. Behavioral Decision (+56979984165, daschwar@dii.uchile.cl), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Screening Engagement Response (time frame: 7 days after message delivery). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jun 2026.